Abstract
P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides. The platelet ADP-receptor which has been denominated P2Y12 receptor is an important target in pharmacotherapy. The receptor couples to Gαi2 mediating an inhibition of cyclic AMP accumulation and additional downstream events including the activation of phosphatidylinositol-3-kinase and Rap1b proteins. The nucleoside analogue ticagrelor and active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel block P2Y12 receptors and, thereby, inhibit ADP-induced platelet aggregation. These drugs are used for the prevention and therapy of cardiovascular events such as acute coronary syndromes or stroke. The recently published three-dimensional crystal structures of the human P2Y12 receptor in complex with agonists and antagonists will facilitate the development of novel therapeutic agents with reduced adverse effects. P2Y12 receptors are also expressed on vascular smooth muscle cells and may be involved in the pathophysiology of atherogenesis. P2Y12 receptors on microglial cells operate as sensors for adenine nucleotides released during brain injury. A recent study indicated the involvement of microglial P2Y12 receptors in the activity-dependent neuronal plasticity. Interestingly, there is evidence for changes in P2Y12 receptor expression in CNS pathologies including Alzheimer’s diseases and multiple sclerosis. P2Y12 receptors may also be involved in systemic immune modulating responses and the susceptibility to develop bronchial asthma.
Abbreviations
- ADPßS:
-
adenosine 5-O-2-thiodiphosphate
- Akt:
-
proteinkinase B
- AR-C66096:
-
2-(propylthio)adenosine-5′-O-(β,γ-difluoromethylene)triphosphate
- AR-C67085:
-
2-propylthio-β,γ-dichloromethylene-D-ATP
- AR-C69931MX:
-
N6-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-β,γ-dichloromethylene-ATP)
- AZD1283:
-
ethyl 6-(4-[(benzylsulfonyl) carbamoyl]piperidin-1-yl)-5-cyano-2-methylnicotinate)
- AZD6140:
-
ticagrelor
- EL:
-
extracellular loops
- FITC:
-
fluorescein isothiocyanate
- GPCRs:
-
G-protein-coupled receptors
- LPS:
-
lipopolysaccharide
- PDZ:
-
postsynaptic density 95/disc large/zonula occludens-1–binding domain
- PSB-0739:
-
1-Amino-9,10-dihydro-9,10-dioxo-4-[[4-(phenylamino)-3-sulfophenyl]amino]-2-anthracenesulfonic acid
- RASA3:
-
Ras GTPase-activating protein 3
- TM:
-
transmembrane regions
References
Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA (2006) International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281–341
Ahn YH, Lee JY, Park HD, Kim TH, Park MC, Choi G, Kim S (2016) Identification of a new morpholine scaffold as a P2Y12 receptor antagonist. Molecules 21:E1114
Algaier I, Jakubowski JA, Asai F, von Kügelgen I (2008) Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost 6:1908–1914
Amadio S, Parisi C, Montilli C, Carrubba AS, Apolloni S, Volonté C (2014) P2Y12 receptor on the verge of a neuroinflammatory breakdown. Mediat Inflamm 2014:975849
Amison RT, Momi S, Morris A, Manni G, Keir S, Gresele P, Page CP, Pitchford SC (2015) RhoA signaling through platelet P2Y1 receptor controls leukocyte recruitment in allergic mice. J Allergy Clin Immunol 135:528–538
Amisten S, Braun OO, Johansson L, Ridderstråle M, Melander O, Erlinge D (2008) The P2Y 13 Met-158-Thr polymorphism, which is in linkage disequilibrium with the P2Y 12 locus, is not associated with acute myocardial infarction. PLoS One 3:e1462
Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, Conley PB (2003) P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 112:398–406
Angiolillo DJ, Franchi F, Waksman R, Sweeny JM, Raveendran G, Teng R, Zhao Y, Carlson G, Khan N, Mehran R (2016) Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing ad hoc PCI. J Am Coll Cardiol 67:603–613
Aungraheeta R, Conibear A, Butler M, Kelly E, Nylander S, Mumford A, Mundell SJ (2016) Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood 128:2717–2728
Bach P, Boström J, Brickmann K, van Giezen JJ, Groneberg RD, Harvey DM, Harvey DM, O’Sullivan M, Zetterberg F (2013) Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor. Eur J Med Chem 65:360–375
Baqi Y (2016) Anthraquinones as a privileged scaffold in drug discovery targeting nucleotide-binding proteins. Drug Discov Today 21:1571–1577
Baqi Y, Atzler K, Köse M, Glänzel M, Müller CE (2009) High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J Med Chem 52:3784–3793
Baurand A, Eckly A, Hechler B, Kauffenstein G, Galzi JL, Cazenave JP, Léon C, Gachet C (2005) Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol 67:721–733
Bednar F, Kroupa J, Ondrakova M, Osmancik P, Kopa M, Motovska Z (2016) Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. J Thromb Thrombolysis 41:549–555
Beko K, Koványi B, Gölöncsér F, Horváth G, Dénes Á, Környei Z, Botz B, Helyes Z, Müller CE, Sperlágh B (2017) Contribution of platelet P2Y12 receptors to chronic complete Freund’s adjuvant-induced inflammatory pain. J Thromb Haemost 15:1223–1235
Ben Addi A, Cammarata D, Conley PB, Boeynaems JM, Robaye B (2010) Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP. J Immunol 185:5900–5906
Bijak M, Szelenberger R, Saluk J, Nowak P (2017) Flavonolignans inhibit ADP induced blood platelets activation and aggregation in whole blood. Int J Biol Macromol 95:682–688
Björquist A, Di Buduo CA, Femia EA, Storey RF, Becker RC, Balduini A, Nylander S, Cattaneo M (2016) Studies of the interaction of ticagrelor with the P2Y13 receptor and with P2Y13-dependent pro-platelet formation by human megakaryocytes. Thromb Haemost 116:1079–1088
Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, Harden TK (2003) Purification and functional reconstitution of the human P2Y12 receptor. Mol Pharmacol 64:1210–1216
Born GV (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927–929
Bunyavanich S, Boyce JA, Raby BA, Weiss ST (2012) Gene-by-environment effect of house dust mite on purinergic receptor P2Y12 (P2RY12) and lung function in children with asthma. Clin Exp Allergy 42:229–437
Burnstock G (2007) Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87:659–797
Burnstock G (2015) Blood cells: an historical account of the roles of purinergic signalling. Purinergic Signal 11:411–434
Burnstock G, Boeynaems JM (2014) Purinergic signalling and immune cells. Purinergic Signal 10:529–564
Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, PM W, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL (2014) Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci 17:131–143
Cameron L (2012) The LTE(4)-P2Y12 pathway in asthma. Clin Exp Allergy 42:176–179
Caroff E, Meyer E, Treiber A, Hilpert K, Riederer MA (2014) Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation. Bioorg Med Chem Lett 24:4323–4331
Caroff E, Hubler F, Meyer E, Renneberg D, Gnerre C, Treiber A, Rey M, Hess P, Steiner B, Hilpert K, Riederer MA (2015) 4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic acid butyl ester (ACT-246475) and its prodrug (ACT-281959), a novel P2Y12 receptor antagonist with a wider therapeutic window in the rat than clopidogrel. J Med Chem 58:9133–9153
Cattaneo M (2011) The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 117:2102–2112
Cattaneo M (2015) The platelet P2 receptors in inflammation. Hamostaseologie 2015:262–266
Cattaneo M, Faioni EM (2012) Why does ticagrelor induce dyspnea? Thromb Haemost 108:1031–1036
Cattaneo M, Lecchi A (2007) Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 5:577–582
Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J, Ruggeri ZM (2003) Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci U S A 100:1978–1983
Chan MV, Knowles RBM, Lundberg MH, Tucker AT, Mohamed NA, Kirkby NS, Armstrong PCJ, Mitchell JA, Warner TD (2015) P2Y12 Receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. Br J Clin Pharmacol 81:621–633
Chhatriwala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA, Harden TK (2004) Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther 311:1038–1043
Cooper DM, Rodbell M (1979) ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase. Nature 282:517–518
Cöster M, Wittkopf D, Kreuchwig A, Kleinau G, Thor D, Krause G, Schöneberg T (2012) Using ortholog sequence data to predict the functional relevance of mutations in G-protein-coupled receptors. FASEB J 26:3273–3281
Crepaldi P, Cacciari B, Bonache MC, Spalluto G, Varani K, Borea PA, von Kügelgen I, Hoffmann K, Pugliano M, Razzari C, Cattaneo M (2009) 6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors. Bioorg Med Chem 17:4612–4621
Daly ME, Dawood BB, Lester WA, Peake IR, Rodeghiero F, Goodeve AC, Makris M, Wilde JT, Mumford AD, Watson SP, Mundell SJ (2009) Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood 113:4110–4113
Diehl P, Olivier C, Halscheid C, Helbing T, Bode C, Moser M (2010) Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res Cardiol 105:379–387
Ding Z, Bynagari YS, Mada SR, Jakubowski JA, Kunapuli SP (2009) Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists. J Thromb Haemost 7:232–234
Dorsam RT, Kunapuli SP (2004) Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113:340–345
El-Tayeb A, Griessmeier KJ, Müller CE (2005) Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors. Bioorg Med Chem Lett 15:5450–5452
Eyo UB, Peng J, Swiatkowski P, Mukherjee A, Bispo A, LJ W (2014) Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus. J Neurosci 34:10528–10540
Eyo UB, Gu N, De S, Dong H, Richardson JR, LJ W (2015) Modulation of microglial process convergence toward neuronal dendrites by extracellular calcium. J Neurosci 35:2417–2422
Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989–995
Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS (2001) Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107:1591–1598
Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA (1961) Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 192:531–532
Gachet C (2006) Regulation of platelet functions by P2 receptors. Ann Rev Pharmacol Toxicol 46:277–300
Gebremeske S, LeVatte T, Liwski RS, Johnston B, Bezuhly M (2015) The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer 136:234–240
Gelosa P, Lecca D, Fumagalli M, Wypych D, Pignieri A, Cimino M, Verderio C, Enerbäck M, Nikookhesal E, Tremoli E, Abbracchio MP, Sironi L (2014) Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor. J Cereb Blood Flow Metab 34:979–988
Gremmel T, Yanachkov IB, Yanachkova MI, Wright GE, Wider J, Undyala VVR, Michelson AD, Frelinger AL, Przyklenk K (2016) Synergistic inhibition of both P2Y1 and P2Y12 adenosine diphosphate receptors as novel approach to rapidly attenuate platelet-mediated thrombosis. Arterioscler Thromb Vasc Biol 36:501–509
Gu N, Eyo UB, Murugan M, Peng J, Matta S, Dong H, LJ W (2016) Microglial P2Y12 receptors regulate microglial activation and surveillance during neuropathic pain. Brain Behav Immun 55:82–92
Guidetti GF, Lova P, Bernardi B, Campus F, Baldanzi G, Graziani A, Balduini C, Torti M (2008) The Gi-coupled P2Y12 receptor regulates diacylglycerol-mediated signaling in human platelets. J Biol Chem 283:28795–28805
Gündüz D, Tanislav C, Sedding D, Parahuleva M, Santoso S, Troidl C, Hamm CW, Aslam M (2017a) Uridine triphosphate Thio analogues inhibit platelet P2Y12 receptor and aggregation. Int J Mol Sci 18:E269
Gündüz D, Tanislav C, Schluter KD, Schulz R, Hamm C, Aslam M (2017b) Effect of ticagrelor on endothelial calcium signalling and barrier function. Thromb Haemost 117:371–381
Hashimoto M, Sugidachi A, Isobe T, Niitsu Y, Ogawa T, Jakubowski JA, Asai F (2007) The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel. Biochem Pharmacol 74:1003–1009
Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, Julius D (2006) The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci 9:1512–1519
Hechler B, Gachet C (2015) Purinergic receptors in thrombosis and inflammation. Arterioscler Thromb Vasc Biol 35:2307–2315
Herbert JM, Tissinier A, Defreyn G, Maffrand JP (1993) Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 13:1171–1179
Hoffmann K, Sixel U, Di Pasquale F, von Kügelgen I (2008) Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y12-receptor. Biochem Pharmacol 76:1201–1213
Hoffmann K, Baqi Y, Morena MS, Glänzel M, Müller CE, von Kügelgen I (2009) Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. J Pharmacol Exp Ther 331:648–655
Hoffmann K, Lutz DA, Straßburger J, Baqi Y, Müller CE, von Kügelgen I (2014) Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor. J Thromb Haemost 12:1898–1905
Högberg C, Gidlöf O, Deflorian F, Jacobson KA, Abdelrahman A, Müller CE, Olde B, Erlinge D (2012) Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y12 receptor-mediated platelet aggregation. Thromb Haemost 108:119–132
Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202–207
Honda S, Sasaki Y, Ohsawa K, Imai Y, Nakamura Y, Inoue K, Kohsaka S (2001) Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J Neurosci 21:1975–1982
Horváth G, Gölöncsér F, Csölle C, Király K, Andó RD, Baranyi M, Koványi B, Máté Z, Hoffmann K, Algaier I, Baqi Y, Müller CE, von Kügelgen I, Sperlágh B (2014) Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents. Neurobiol Dis 70:162–178
Idzko M, Ferrari D, Eltzschig HK (2014) Nucleotide signalling during inflammation. Nature 509:310–317
Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ, Willis PA, Humphries RG, Leff P, Clegg JA, Smith JA, Tomlinson W (1999) Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 42:213–220
Jacobson KA, Paoletta S, Katritch V, Wu B, Gao ZG, Zhao Q, Stevens RC, Kiselev E (2015) Nucleotides acting at P2Y receptors: connecting structure and function. Mol Pharmacol 88:220–230
James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L (2009) Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J 157:599–605
Jorgensen NR, Grove EL, Schwarz P, Vestergaard P (2012) Clopidogrel and the risk of osteoporotic fractures: a nationwide cohort study. J Intern Med 272:385–393
Kamae T, Shiraga M, Kashiwagi H, Kato H, Tadokoro S, Kurata Y, Tomiyama Y, Kanakura Y (2006) Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: association with Rap1B activation. J Thromb Haemost 4:1379–1387
Kauffenstein G, Hechler B, Cazenave JP, Gachet C (2004) Adenine triphosphate nucleotides are antagonists at the P2Y12 receptor. J Thromb Haemost 2:1980–1988
Kawaguchi A, Sato M, Kimura M, Ichinohe T, Tazaki M, Shibukaw Y (2015) Expression and function of purinergic P2Y12 receptors in rat trigeminal ganglion neurons. Neurosci Res 98:17–27
Khan A, Li D, Ibrahim S, Smyth E, Woulfe DS (2014) The physical association of the P2Y12 receptor with PAR4 regulates arrestin-mediated Akt activation. Mol Pharmacol 86:1–11
Kim S, Kunapuli SP (2011) P2Y12 Receptor in platelet activation. Platelets 22:56–60
Kirkby NS, Lundberg MH, Chan MV, Vojnovic I, Solomon AB, Emerson M, Mitchell JA, Warner TD (2013) Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A 110:15782–15787
Knauer KA, Fish JE, Adkinson NF Jr, Lichtenstein LM, Peters SP, Newball HH (1981) Platelet activation in antigen-induced bronchoconstriction. N Engl J Med 305:892–893
Koizumi S, Ohsawa K, Inoue K, Kohsaka S (2013) Purinergic receptors in microglia: functional modal shifts of microglia mediated by P2 and P1 receptors. Glia 61:47–54
Kubista H, Lechner SG, Wolf AM, Boehm S (2003) Attenuation of the P2Y receptor-mediated control of neuronal Ca2+ channels in PC12 cells by antithrombotic drugs. Br J Pharmacol 138:343–350
Kulick MB, von Kügelgen I (2002) P2Y-Receptors mediating an inhibition of the evoked entry of calcium through N-type calcium channels at neuronal processes. J Pharmacol Exp Ther 303:520–526
Lecchi A, Razzari C, Paoletta S, Dupuis A, Nakamura L, Ohlmann P, Gachet C, Jacobson KA, Zieger B, Cattaneo M (2015) Identification of a new dysfunctional platelet P2Y12 receptor variant associated with bleeding diathesis. Blood 125:1006–1013
Lechner SG, Dorostkar MM, Mayer M, Edelbauer H, Pankevych H, Boehm S (2004) Autoinhibition of transmitter release from PC12 cells and sympathetic neurons through a P2Y receptor-mediated inhibition of voltage-gated Ca2+ channels. Eur J Neurosci 20:2917–2928
Liu M, Yao M, Wang H, Xu L, Zheng Y, Huang B, Ni H, Xu S, Zhou X, Lian Q (2017) P2Y12 receptor-mediated activation of spinal microglia and p38MAPK pathway contribute to cancer-induced bone pain. J Pain Res 10:417–426
Liverani E, Rico MC, Garcia AE, Kilpatrick LE, Kunapuli SP (2013) Prasugrel metabolites inhibit neutrophil functions. J Pharmacol Exp Ther 344:231–243
Liverani E, Kilpatrick LE, Tsygankov AY, Kunapuli SP (2014a) The role of P2Y12 receptor and activated platelets during inflammation. Curr Drug Targets 15:720–728
Liverani E, Rico MC, Yaratha L, Tsygankov AY, Kilpatrick LE, Kunapuli SP (2014b) LPS-induced systemic inflammation is more severe in P2Y12 null mice. J Leukoc Biol 95:313–323
Liverani E, Rico MC, Tsygankov AY, Kilpatrick LE, Kunapuli SP (2016) P2Y12 Receptor modulates sepsis-induced inflammation. Arterioscler Thromb Vasc Biol 36:961–971
Lou N, Takano T, Pei Y, Al X, Goldman SA, Nedergaard M (2016) Purinergic receptor P2RY12-dependent microglial closure of the injured blood–brain barrier. Proc Natl Acad Sci U S A 113:1074–1079
Lussana F, Di Marco F, Terraneo S, Parati M, Razzari C, Scavone M, Femia EA, Moro A, Centanni S, Cattaneo M (2015) Effect of prasugrel in patients with asthma: results of PRINA, a randomized, double-blind, placebo-controlled, cross-over study. J Thromb Haemost 13:136–141
Maffrand JP, Bernat A, Delebassee D, Defreyn G, Cazenave JP, Gordon JL (1988) ADP plays a key role in thrombogenesis in rats. Thromb Haemost 59:225–230
Marteau F, Le Poul E, Communi D, Communi D, Labouret C, Savi P, Boeynaems JM, Gonzalez NS (2003) Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol 64:104–112
Mildner A, Huang H, Radke J, Stenzel W, Priller J (2017) P2Y12 receptor is expressed on human microglia under physiological conditions throughout development and is sensitive to neuroinflammatory diseases. Glia 65:375–387
Mitchell C, Syed NI, Tengah A, Gurney AM, Kennedy C (2012) Identification of contractile P2Y1, P2Y6, and P2Y12 receptors in rat intrapulmonary artery using selective ligands. J Pharmacol Exp Ther 343:755–762
Moore CS, Ase AR, Kinsara A, Rao VTS, Michell-Robinson M, Leong SY, Butovsky O, Ludwin SK, Séguéla P, Bar-Or A, Antel JP (2015) P2Y12 Expression and function in alternatively activated human microglia. Neurol Neuroimmunol Neuroinflamm 2:e80
Müller CE (2002) P2-Pyrimidinergic receptors and their ligands. Curr Pharm Des 8:2353–2369
Mundell SJ, Jones ML, Hardy AR, Barton JF, Beaucourt SM, Conley PB, Poole AW (2006) Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function. Mol Pharmacol 70:1132–1142
Mundell SJ, Barton JF, Mayo-Martin MB, Hardy AR, Poole AW (2008) Rapid resensitization of purinergic receptor function in human platelets. J Thromb Haemost 6:1393–1404
Nicholas RA (2015) Insights into platelet P2Y12 receptor activation. Blood 125:893–895
Niitsu Y, Jakubowski JA, Sugidachi A, Asai F (2005) Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 31:184–194
Nisar S, Daly ME, Federici AB, Artoni A, Mumford AD, Watson SP, Mundell SJ (2011) An intact PDZ motif is essential for correct P2Y12 purinoceptor traffic in human platelets. Blood 118:5641–5651
Niu X, Pi SL, Baral S, Xia YP, He QW, Li YN, Jin HJ, Li M, Wang MD, Mao L, Hu B (2017) P2Y12 promotes migration of vascular smooth muscle cells through cofilin dephosphorylation during atherogenesis. Arterioscler Thromb Vasc Biol 37:515–524
Nylander S, Mattsson C, Ramstrom S, Lindahl TL (2003) The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation. Thromb Res 111:65–73
Nylander S, Mattsson C, Ramström S, Lindahl TL (2004) Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol 142:1325–1331
Ohlmann P, Lecchi A, El-Tayeb A, Müller CE, Cattaneo M, Gachet C (2013) The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413. Purinergic Signal 9:59–66
Ohsawa K, Irino Y, Sanagi T, Nakamura Y, Suzuki E, Inoue K, Kohsaka S (2010) P2Y12 receptor-mediated integrin-beta1 activation regulates microglial process extension induced by ATP. Glia 58:790–801
Olivier CB, Diehl P, Schnabel K, Weik P, Zhou Q, Bode C, Moser M (2014) Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thromb Haemost 111:266–272
Ou W, He Y, Li A, Liu B, Jin L (2016) Genotype frequencies of CYP2C19, P2Y12 and GPIIIa polymorphisms in coronary heart disease patients of Han ethnicity, and their impact on Clopidogrel responsiveness. Int Heart J 57:586–592
Paoletta S, Sabbadin D, von Kügelgen I, Hinz S, Katritch V, Hoffmann K, Abdelrahman A, Straßburger J, Baqi Y, Zhao Q, Stevens RC, Moro S, Müller CE, Jacobson KA (2015) Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information. J Comput Aided Mol Des 29:737–756
Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP (2008) Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454:183–187
Parker WA, Bhatt DL, Prats J, Day JR, Steg PG, Stone GW, Hamm CW, Mahaffey KW, Price MJ, Gibson CM, White HD, Storey RF (2017) Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thromb Haemost 117:1093–1100
Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Harris PK, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD (2010) Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation. J Med Chem 53:2010–2037
Patel YM, Lordkipanidzé M, Lowe GC, Nisar SP, Garner K, Stockley J, Daly ME, Mitchell M, Watson SP, Austin SK, Mundell SJ (2014) A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in protease-activated receptor 1 in a patient with chronic bleeding. J Thromb Haemost 12:716–725
Pedata F, Dettori I, Coppi E, Melani A, Fusco I, Corradetti R, Pugliese AM (2016) Purinergic signalling in brain ischemia. Neuropharmacology 104:105–130
Pitchford SC, Momi S, Baglioni S, Casali L, Giannini S, Rossi R, Page CP, Gresele P (2008) Allergen induces the migration of platelets to lung tissue in allergic asthma. Am J Respir Crit Care Med 177:604–612
Qin C, Zhou J, Gao Y, Lai W, Yang C, Cai Y, Chen S, Du C (2017) Critical role of P2Y12 receptor in regulation of Th17 differentiation and experimental autoimmune encephalomyelitis pathogenesis. J Immunol 199:72–81
Quintas C, Fraga S, Gonçalves J, Queiroz G (2009) The P2Y1 and P2Y12 receptors mediate autoinhibition of transmitter release in sympathetic innervated tissues. Neurochem Int 55:505–513
Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413–492
Ralevic V, Burnstock G (2003) Involvement of purinergic signaling in cardiovascular diseases. Drug News Perspect 16:133–140
Rauch BH, Rosenkranz AC, Ermler S, Böhm A, Driessen J, Fischer JW, Sugidachi A, Jakubowski JA, Schrör K (2010) Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. Arterioscler Thromb Vasc Biol 30:2434–2442
Remijn JA, IJsseldijk MJ, Strunk AL, Abbes AP, Engel H, Dikkeschei B, Dompeling EC, de Groot PG, Slingerland RJ (2007) Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis. Clin Chem Lab Med 45:187–189
Sasaki Y, Hoshi M, Akazawa C, Nakamura Y, Tsuzuki H, Inoue K, Kohsaka S (2003) Selective expression of Gi/o-coupled ATP receptor P2Y12 in microglia in rat brain. Glia 44:242–250
Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Hervé C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P, Herbert JM (2006) The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A 103:11069–11074
Scavone M, Femia EA, Cattaneo M (2017) P2Y12 Receptor gene mutations associated with bleeding. Platelets 28:421–423
Schmidt P, Ritscher L, Dong EN, Hermsdorf T, Cöster M, Wittkopf D, Meiler J, Schöneberg T (2013) Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12. Mol Pharmacol 83:256–266
Shanker G, Kontos JL, Eckman DM, Wesley-Farrington D, Sane DC (2006) Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis 22:213–220
Siasos G, Kioufis S, Oikonomou E, Zaromitidou M, Maniatis K, Vavuranakis M, Kokkou E, Tousoulis D (2016) Impact of C34T P2Y12 ADP receptor polymorphism and smoking status on cardiovascular outcome in coronary artery disease patients receiving clopidogrel. Int J Cardiol 210:161–163
Simon J, Vigne P, Eklund KM, Michel AD, Carruthers AM, Humphrey PP, Frelin C, Barnard EA (2001) Activity of adenosine diphosphates and triphosphates on a P2Y(T)-type receptor in brain capillary endothelial cells. Br J Pharmacol 132:173–182
Sipe GO, Lowery RL, Tremblay MÈ, Kelly EA, Lamantia CE, Majewska AK (2016) Microglial P2Y12 is necessary for synaptic plasticity in mouse visual cortex. Nat Commun 7:10905
Sirotkina OV, Laskovets AB, Andoskin PA, Emelyanov AK, Zabotina AM, Vavilova TV (2016) Increase in GP IIb-IIIa and P2Y12 receptors in activated platelets as the possible indicator of de novo protein synthesis. Mol Biol 50:111–117
Smith TH, Li JG, Dores MR, Trejo J (2017) Protease-activated receptor-4 and P2Y12 dimerize, co-internalize and activate Akt signaling via endosomal recruitment of β-arrestin. J Biol Chem 292:13867–13878. doi:10.1074
Södergren AL, Holm ACS, Ramström S, Lindström EG, Grenegård M, Öllinger K (2016) Thrombin-induced lysosomal exocytosis in human platelets is dependent on secondary activation by ADP and regulated by endothelial-derived substances. Platelets 27:86–92
Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD, Humphries RG, Hunt SF, Ince F, Ingall AH, Kirk IP, Leeson PD, Leff P, Lewis RJ, Martin BP, McGinnity DF, Mortimore MP, Paine SW, Pairaudeau G, Patel A, Rigby AJ, Riley RJ, Teobald BJ, Tomlinson W, Webborn PJ, Willis PA (2007) From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 17:6013–6018
Stefanini L, Bergmeier W (2016) RAP1-GTPase signaling and platelet function. J Mol Med (Berl) 94:13–19
Stefanini L, Paul DS, Robledo RF, Chan ER, Getz TM, Campbell RA, Kechele DO, Casari C, Piatt R, Caron KM, Mackman N, Weyrich AS, Parrott MC, Boulaftali Y, Adams MD, Peters LL, Bergmeier W (2015) RASA3 Is a critical inhibitor of RAP1-dependent platelet activation. J Clin Invest 125:1419–1432
Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN (2012) The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest 122:3579–3592
Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H (2000) The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 129:1439–1446
Sugidachi A, Mizuno M, Ohno K, Jakubowski JA, Tomizawa A (2016) The active metabolite of prasugrel, R-138727, improves cerebral blood flow and reduces cerebral infarction and neurologic deficits in a non-human primate model of acute ischaemic stroke. Eur J Pharmacol 788:132–139
Suh DH, Trinh HK, Liu JN, Phamle D, Park SM, Park HS, Shin YS (2016) P2Y12 antagonist attenuates eosinophilic inflammation and airway hyperresponsiveness in a mouse model of asthma. J Cell Mol Med 20:333–341
Sunkaria A, Bhardwaj S, Halder A, Yadav A, Sandhir R (2016) Migration and phagocytic ability of activated microglia during post-natal development is mediated by calcium-dependent purinergic signalling. Mol Neurobiol 53:944–954
Swiatkowski P, Murugan M, Eyo UB, Wang Y, Rangaraju S, SB O, LJ W (2016) Activation of microglial P2Y12 receptor is required for outward potassium currents in response to neuronal injury. Neuroscience 318:22–33
Syberg S, Brandao-Burch A, Patel JJ, Hajjawi M, Arnett TR, Schwarz P, Jorgensen NR, Orriss IR (2012) Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. J Bone Miner Res 27:2373–2386
Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Matsushime H, Furuichi K (2001) Molecular cloning of the platelet P2TAC ADP receptor: pharmacological comparison with another ADP receptor, the P2Y1 receptor. Mol Pharmacol 60:432–439
Tamagawa T, Shinoda M, Honda K, Furukawa A, Kaji K, Nagashima H, Akasaka R, Chen J, Sessle BJ, Yonehara Y, Iwata K (2016) Involvement of microglial P2Y12 signaling in tongue cancer pain. J Dent Res 95:1176–1182
Tatsumi E, Yamanaka H, Kobayashi K, Yagi H, Sakagami M, Noguchi K (2015) RhoA/ROCK pathway mediates p38 MAPK activation and morphological changes downstream of P2Y12/13 receptors in spinal microglia in neuropathic pain. Glia 63:216–228
Thomas MR, Storey RF (2015) Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost 114:490–497
Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Kohsaka S, Inoue K (2008) P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. J Neurosci 28:4949–4956
Tozaki-Saitoh H, Miyata H, Yamashita T, Matsushita K, Tsuda M, Inoue K (2017) P2Y12 receptors in primary microglia activate nuclear factor of activated T cell signaling to induce C-C chemokine 3 expression. J Neurochem 141:100–110
Tsuda M, Inoue K (2016) Neuron-microglia interaction by purinergic signaling in neuropathic pain following neurodegeneration. Neuropharmacology 104:76–81
Uehara K, Uehara A (2011) P2Y1, P2Y6, and P2Y12 receptors in rat splenic sinus endothelial cells: an immunohistochemical and ultrastructural study. Histochem Cell Biol 136:557–567
van Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ (2009) Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7:1556–1565
von Kügelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110:415–432
von Kügelgen I, Harden TK (2011) Molecular pharmacology, physiology, and structure of the P2Y receptors. Adv Pharmacol 61:373–415
von Kügelgen I, Hoffmann K (2016) Pharmacology and structure of P2Y receptors. Neuropharmacology 104:50–61
von Kügelgen I, Wetter A (2000) Molecular pharmacology of P2Y-receptors. Naunyn-Schmiedebergs. Arch Pharmacol 362:310–323
Wang L, Östberg O, Wihlborg AK, Brogren H, Jern S, Erlinge D (2003) Quantification of ADP and ATP receptor expression in human platelets. J Thromb Haemost 1:330–336
Wang L, Jacobsen SE, Bengtsson A, Erlinge D (2004) P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 5:16
Webster CM, Hokari M, McManus A, Tang XN, Ma H, Kacimi R, Yenari MA (2013) Microglial P2Y12 deficiency/inhibition protects against brain ischemia. PLoS One 8:e70927
West LE, Steiner T, Judge HM, Francis SE, Storey RF (2014) Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovasc Res 102:429–435
Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D (2004) ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 24:1810–1815
Yanachkov IB, Chang H, Yanachkova MI, Dix EJ, Berny-Lang MA, Gremmel T, Michelson AD, Wright GE, Frelinger AL (2016) New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem 107:204–218
Yang HH, Chen Y, Gao CY (2016) Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel. Cardiovasc Ther 34:460–467
Yi X, Wang Y, Lin J, Cheng W, Zhou Q, Wang C (2016) Interaction of CYP2C19, P2Y12, and GPIIIa variants associates with efficacy of clopidogrel and adverse events on patients with ischemic stroke. Clin Appl Thromb Hemost 1076029616648408
Yi X, Zhou Q, Wang C, Lin J, Liu P, Fu C (2017) Platelet receptor gene (P2Y12, P2Y1) and platelet glycoprotein gene (GPIIIa) polymorphisms are associated with antiplatelet drug responsiveness and clinical outcomes after acute minor ischemic stroke. Eur J Clin Pharmacol 73:437–443
Zech G, Hessler G, Evers A, Weiss T, Florian P, Just M, Czech J, Czechtizky W, Görlitzer J, Ruf S, Kohlmann M, Nazare M (2012) Identification of high-affinity P2Y12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone. J Med Chem 55:8615
Zetterberg F, Svensson P (2016) State of affairs: design and structure–activity relationships of reversible P2Y12 receptor antagonists. Bioorg Med Chem Lett 26:2739–2754
Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu YH, Chen G, Pramanik B, Laz TM, Palmer K, Bayne M, Monsma FJ (2001) ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 276:8608–8615
Zhang K, Zhang J, Gao ZG, Zhang D, Zhu L, Han GW, Moss SM, Paoletta S, Kiselev E, Lu W, Fenalti G, Zhang W, Müller CE, Yang H, Jiang H, Cherezov V, Katritch V, Jacobson KA, Stevens RC, Wu B, Zhao Q (2014a) Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature 509:115–118
Zhang J, Zhang K, Gao ZG, Paoletta S, Zhang D, Han GW, Li T, Ma L, Zhang W, Müller CE, Yang H, Jiang H, Cherezov V, Katritch V, Jacobson KA, Stevens RC, Wu B, Zhao Q (2014b) Agonist-bound structure of the human P2Y12 receptor. Nature 509:119–122
Zhang Y, Peti-Peterdi J, Müller CE, Carlson NG, Baqi Y, Strasburg DL, Heiney KM, Villanueva K, Kohan DE, Kishore BK (2015) P2Y12 receptor localizes in the renal collecting duct and its blockade augments arginine vasopressin action and alleviates nephrogenic diabetes insipidus. J Am Soc Nephrol 26:2978–2987
Zhang Z, Wu G, Wang C, Jin X, Li D, Lin K (2016) Features of reversible P2Y12 receptor antagonists based on piperazinyl-glutamate-pyridines. Med Chem Res 25:1204–1215
Zhang J, Li Z, Hu X, Su Q, He C, Liu J, Ren H, Qian M, Liu J, Cui S, Jiang W (2017) Knockout of P2Y12 aggravates experimental autoimmune encephalomyelitis in mice via increasing of IL-23 production and Th17 cell differentiation by dendritic cells. Brain Behav Immunol 62:245–255
Zhou S, Fang D, Tan S, Lin W, Wu W, Zheng K (2016) Investigating the binding mechanism of novel 6-aminonicotinate-based antagonists with P2Y12 by 3D-QSAR, docking and molecular dynamics simulations. J Biomol Struct Dyn 30:1–28
Compliance with Ethical Standards
Conflicts of Interest
The author declares that he has no conflicts of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by the author.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
von Kügelgen, I. (2017). Structure, Pharmacology and Roles in Physiology of the P2Y12 Receptor. In: Atassi, M. (eds) Protein Reviews. Advances in Experimental Medicine and Biology(), vol 1051. Springer, Singapore. https://doi.org/10.1007/5584_2017_98
Download citation
DOI: https://doi.org/10.1007/5584_2017_98
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-7610-7
Online ISBN: 978-981-10-7611-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)